Practice
Clinical updates, guidelines, prescribing, and practical medicine
Experimental Drug DT-109 Reverses Severe Fatty Liver Disease by Repairing Gut Barrier in Animal Studies
An experimental compound called DT-109 reversed severe fatty liver disease in preclinical animal models by restoring intestinal barrier integrity and…
Editor's Top Picks
Engineered Islet Transplant Survives Without Immunosuppression in First-in-Human Trial
A first-in-human trial published in the New England Journal of Medicine demonstrates long-term survival of genetically engineered pancreatic islet cells…
Submit Your Paper →
More form Practice
ARPA-H funds $160 million gene-editing push for rare diseases after administrative delays
The U.S. Advanced Research Projects Agency for Health (ARPA-H) is awarding $160 million to seven…
mRNA Cancer Vaccines Harness Unexpected Immune Backup System, Study Finds
Researchers have identified an unexpected immune cell type recruited by mRNA cancer vaccines, challenging conventional…
ACA Insurers Seek Double-Digit Premium Increases as Enrollment Declines
For the second consecutive year, many Affordable Care Act insurers are proposing double-digit premium increases,…
Socioeconomic Status Shapes Childhood Obesity Treatment Outcomes in Europe
A two-country study of over 31,000 children finds that socioeconomic status predicts obesity treatment success…
KRAS-G12D inhibitor shows promise in advanced pancreatic cancer: phase 1b/2 trial results
A phase 1b/2 trial published in Nature Medicine demonstrates that HRS-4642, a targeted KRAS-G12D inhibitor…